We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Transfusion Practice Wastes Scarce Plasma

By LabMedica International staff writers
Posted on 30 Jul 2013
Print article
Image: Donor Blood Separation (Photo courtesy of Puget Sound Blood Center).
Image: Donor Blood Separation (Photo courtesy of Puget Sound Blood Center).
The use of a blood transfusion protocol in patients with severe trauma is feasible in hospitals, although it is associated with higher waste of plasma.

The protocol, in use since 2007, uses an equal ratio of red blood cells, plasma, and platelets to transfuse patients, yet this 1:1:1 ratio is associated with higher waste of donated blood plasma.

Scientists at the Sunnybrook Health Sciences Center (Toronto, ON, Canada) conducted a randomized trial to determine feasibility and safety of 1:1:1 ratio in 78 patients presenting in a large trauma center, with low blood pressure and substantial bleeding who were expected to need massive blood transfusion. Forty patients were randomly assigned to the fixed-ratio transfusion, and the remaining 38 underwent the laboratory-guided transfusion protocol at the center.

Thawed type AB plasma, a scarce resource, is needed for 1:1:1 transfusion, which also involves delays because of the need to thaw the material. Deaths from all causes after 28 days was higher in the fixed-ratio group at 32.5% compared with 14% in the control group and there was a higher rate of respiratory distress in the patients receiving 1:1:1.


Sandro Rizoli, MD, PhD, a professor of surgery and senior author of the study, said, “These findings suggest that a fixed-ratio transfusion protocol is feasible, but it was associated with increased plasma wastage, about two units per patient”. Widespread adoption of the 1:1:1 strategy has significant resource and safety implications. Its full implementation requires access to thawed type AB plasma, which is chronically in short supply. The 1:1:1 transfusion protocol may lead to unnecessary exposure to blood components and an increased risk of acute respiratory distress syndrome, sepsis, and multiple organ dysfunctions.

The authors concluded that the randomized controlled trial showed the implementation of a fixed-ratio (1:1:1) transfusion protocol was feasible among patients with severe trauma. The full and widespread implementation of such a protocol will challenge blood suppliers because of the increased demand and wastage of plasma. Larger clinical trials are warranted to definitively evaluate the efficacy and safety of transfusion at a 1:1:1 ratio. The study was published on July 15, 2013, in the Canadian Medical Association Journal.

Related Links:
Sunnybrook Health Sciences Center


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
ACTH Assay
ACTH ELISA
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.